SCHEMBL8685698

SCHEMBL8685698

COc1ccc(COS(C)(=O)=O)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.55
SMN1; SMN2 Q16637 4/20 0.50
CA1 P00915 2/20 0.50
CA9 Q16790 2/20 0.50
CA12 O43570 1/20 0.50
CA5A P35218 1/20 0.50
CA14 Q9ULX7 1/20 0.50
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.49
ATM Q13315 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 2/20 0.47
LDHA P00338 1/20 0.47
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
POLB P06746 2/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP19A1 P11511 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2617468 0.85 ABCB1 (0.54) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL3457432 0.85 XDH (0.44) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL17913604 0.85 CA5A (0.39) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL15898811 0.84 PDE4B (0.54) POLB
SCHEMBL3458432 0.84 RECQL (0.54)
SCHEMBL2959929 0.83 CA2 (0.55) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL31490068 0.83 CA2 (0.55) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL3459059 0.83 PDE4B (0.47) SMN1; SMN2LMNAMAPT
SCHEMBL17610838 0.81 AR (0.43) KDM4EALDH1A1
SCHEMBL27400812 0.81 MRGPRX4 (0.45) CA2SMN1; SMN2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024218171-A1 COMPOUNDS WITH ACTIVITY AGAINST SARS-COV-2 NATIONAL HELLENIC RESEARCH FOUNDATION (GR) 2024-10-24 WO disclosed
WO-2013049585-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES HENGRUI (USA), LTD. (US) 2013-04-04 WO disclosed
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
CN-101506134-B Process for producing benzaldehyde compound UBE INDUSTRIES 2012-12-05 CN disclosed
CN-101506134-A Process for producing benzaldehyde compound UBE INDUSTRIES (JP) 2009-08-12 CN disclosed
US-5811439-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS SENGA PHARMACEUTICAL LABORATORY INC. (JP) 1998-09-22 US disclosed
CN-1167111-A Thiazolidinedione derivatives, method for preparing derivatives and pharmaceutical compositions containing same SENGA PHARMACEUTICAL LAB INC (JP) 1997-12-10 CN disclosed
EP-0780389-A1 Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them TOBISHI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES TGM2, CCT5, TSHR CA2 4362/4885SMN1; SMN2 2309/4885CA1 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.